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LAPTM4b recruits the LAT1-4F2hc Leu transporter
to lysosomes and promotes mTORC1 activation
Ruth Milkereit1,*, Avinash Persaud1,*, Liviu Vanoaica2, Adriano Guetg2, Francois Verrey2 & Daniela Rotin1
Mammalian target of rapamycin 1 (mTORC1), a master regulator of cellular growth, is
activated downstream of growth factors, energy signalling and intracellular essential amino
acids (EAAs) such as Leu. mTORC1 activation occurs at the lysosomal membrane, and
involves V-ATPase stimulation by intra-lysosomal EAA (inside-out activation), leading to
activation of the Ragulator, RagA/B-GTP and mTORC1 via Rheb-GTP. How Leu enters the
lysosomes is unknown. Here we identiﬁed the lysosomal protein LAPTM4b as a binding
partner for the Leu transporter, LAT1-4F2hc (SLC7A5-SLAC3A2). We show that LAPTM4b
recruits LAT1-4F2hc to lysosomes, leading to uptake of Leu into lysosomes, and is required
for mTORC1 activation via V-ATPase following EAA or Leu stimulation. These results
demonstrate a functional Leu transporter at the lysosome, and help explain the inside-out
lysosomal activation of mTORC1 by Leu/EAA.
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M
ammalian target of rapamycin 1 (mTORC1) is a
Ser/Thr kinase complex that regulates cellular and
animal growth, and has been implicated in numerous
diseases, including cancer1–3. mTORC1 is a key mediator of
protein translation (and a suppressor of autophagy) downstream
of activated growth factor receptor, energy mediators and amino-
acid inﬂux4,5. Inﬂux of essential amino acids (EAAs), such as
leucine (Leu), into cells is mediated by the LAT1-4F2hc(CD98)
(SLC7A5-SLC3A2, or System L) transporter6,7 in exchange for
Gln8 or other non-EAAs. This Leu entry results in the
recruitment of the mTORC1 complex to the lysosomal
membrane by Rag GTPases9,10. Importantly, cellular inﬂux of
Leu/EAA leads to their subsequent entry into lysosomes, where
they activate the lysosomal membrane protein HþATPase
(V-ATPase) from inside the lysosome (inside-out activation)11,
leading to activation of the Ragulator, RagA/B-GTP and
mTORC1 via Rheb-GTP. This activation stimulates
phosphorylation of S6K1 and 4E-BP, and enhancement of
protein translation12. mTORC1 activation also leads to
inhibition of AMPK and autophagy13. A critical unsolved
question has been how Leu/EAA enters the lysosomes in the
ﬁrst place to promote activation of mTORC1 via V-ATPase.
The lysosomal-associated transmembrane protein 4b
(LAPTM4b) is a lysosomal membrane protein that comprises
four transmembrane domains. It has several splice isoforms,
including a 35- and a 24-kDa variant that are identical except for
a 91-residue N-terminal extension in the former14. The 35-kDa
isoform is overexpressed in numerous tumour types and its gene
is ampliﬁed in breast cancer15,16. It was proposed to promote
cancer by stimulating the PI3K/Akt pathway17. Whether the short
(24 kDa) isoform of LAPTM4b, studied here, is also involved in
promoting cancer is not known. LAPTM4b is mainly localized at
the lysosomal membrane, but a fraction of the protein is also
found at the plasma membrane; LAPTM4b lysosomal localization
is mediated, in part, by its interaction with the ubiquitin ligase
Nedd4 (ref. 18).
Here we show that LAPTM4b binds to LAT1-4F2hc and
recruits this Leu transporter to lysosomes, promoting Leu entry
into lysosomes and activation of mTORC1 via V-ATPase.
Results
LAPTM4b binds the Leu transporter. To investigate the cellular
functions of LAPTM4b, we searched for binding partners of the
24-kDa isoform using mass spectrometry, and identiﬁed
4F2hc/CD98 (SLC3A2) and LAT1 (SLC7A5) as LAPTM4b-
associated proteins (Supplementary Table 1). We validated these
interactions by co-immunoprecipitation (co-IP) of tagged
LAPTM4b and LAT1 or 4F2hc transfected into mammalian
(HeLa) cells (Fig. 1; Supplementary Fig. 1a), as well as co-IP of
endogenous LAPTM4b and LAT1 (Supplementary Fig. 1b). No
interaction was seen with other tested amino-acid transporters,
SLC1A5/ASCT2 or SLC38A2/SNAT2, which transport Gln and
other neutral amino acids (Supplementary Fig. 1c,d), suggesting
that LAPTM4b does not bind nonspeciﬁcally to plasma membrane
transporters. The LAPTM4b:LAT1-4F2hc interaction was not
dependent on amino-acid stimulation (Supplementary Fig. 1e,f).
LAPTM4b recruits LAT1-4F2hc to lysosomes. To study the
consequence of the LAPTM4b:LAT1-4F2hc association in cells,
we expressed epitope-tagged versions of these proteins in HeLa
cells to trace their subcellular localization. Strikingly, while LAT1
and 4F2hc were localized to the plasma membrane, as expected,
co-expression of LAPTM4b with these System L components led
to the recruitment of LAT1-4F2hc to lysosomes (Fig. 2a–c;
Supplementary Fig. 2a,b), with some of the Leu transporter
remaining at the plasma membrane (Supplementary Fig. 2f),
as expected. This lysosomal recruitment was also seen for
endogenous LAT1 (Supplementary Fig. 2c–e). Accordingly,
knockdown of LAPTM4b led to reduced lysosomal association of
LAT1 (Supplementary Fig. 3a,b). This lysosomal recruitment of
LAT1-4F2hc did not affect protein stability of LAT1 or 4F2hc, as
assessed by pulse-chase analysis (Supplementary Fig. 4a–c).
LAPTM4b promotes mTORC1 activation. Given our observed
recruitment of LAT1-4F2hc to lysosomes by LAPTM4b (Fig. 2;
Supplementary Fig. 2), we tested whether expression of
LAPTM4b can enhance mTORC1 activation following EAA
stimulation. Thus, we generated stable HeLa cell lines with
knockdown of LAPTM4b by targeting its 30-untranslated region
(Supplementary Fig. 5a). We then starved these knocked-down
cells of serum and nutrients overnight, a procedure that did not
affect their viability (Supplementary Fig. 5b), and stimulated them
with EAA for 15–60min. As seen in Fig. 3a–d, loss of LAPTM4b
led to an inhibition of mTORC1 activation, as determined by
pT389-S6K1 (pp70) phosphorylation (pp70/p70 ratio). Moreover,
reintroduction of LAPTM4b into these knocked-down cells led to
restoration of EAA-induced S6K1 phosphorylation, indicating
that LAPTM4b was able to stimulate mTORC1 activation, an
effect also observed by stimulating these cells with Leu alone
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Figure 1 | LAPTM4b binds the Leu transporter (4F2hc and LAT1). (a,b) Co-immunoprecipitation (co-IP) of LAPTM4b with 4F2hc and LAT1: HeLa cells
were transfected (Tfxn) with HA-LAPTM4b and Flag-tagged (a) 4F2hc, or (b) LAT1. Following Flag IP, the presence of co-immunoprecipitated LAPTM4b
was veriﬁed by immunoblotting with HA antibodies. Lower panels depict controls for the IPs, for the amounts of lysates used and for protein loading (actin).
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(Fig. 3g). This effect was also seen with other clones of HeLa cells
generated with different LAPTM4b-directed short hairpin RNAs
(shRNAs) (Supplementary Fig. 5c), suggesting the results are not
due to off-target effects of LAPTM4b knockdown. Furthermore,
knockdown of LAPTM4b in two cancer cell lines known to
overexpress LAPTM4b15,16, the breast cancer MDA-MB-231 and
the hepatic carcinoma HepG2 lines, which also express high levels
of endogenous LAT1 (Supplementary Fig. 6a,b), led to a marked
reduction in S6K1 phosphorylation (Supplementary Fig. 6c–f).
Accordingly, reconstitution of LAPTM4b in LAPTM4b-depleted
MDA-MB-231 cells rescued mTORC1 activation (Supplementary
Fig. 6g). These results demonstrate that the positive effect of
LAPTM4b on mTORC1 activation is not conﬁned to HeLa cells.
We also measured mTORC1 activation by analysing 4E-BP
phosphorylation; 4E-BP is a downstream effector of mTORC1
and its phosphorylation releases its inhibitory association with
the eukaryotic initiation factor eIF-4E, promoting the binding of
eIF-4E to eIF3 and eIF4G and initiation of translation12. As seen
in Fig. 3e,f, phosphorylation of 4E-BP was blocked following
knockdown of LAPTM4b, but was restored in LAPTM4b-
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Figure 2 | LAPTM4b recruits the Leu transporter to lysosomes. (a,b) Recruitment of LAT1 to lysosomes by LAPTM4b. HeLa cells were transfected with
mCherry (mCh) LAT1 (red) alone or with HA-LAPTM4b. Cells were ﬁxed 24 h post transfection and stained for the nucleus (4,6-diamidino-2-phenylindole
(DAPI), cyan), lysosomes (LAMP1, green), plasma membrane (PM, concanavalinA, blue) and LAPTM4b (anti-HA, blue). Scale bar, 15 mm.
(c) Quantiﬁcation of co-localization of LAPTM4b with LAT1 or 4F2hc (Pearson’s coefﬁcient). The immunoﬂuorecence imaging for 4F2hc is shown in
Supplementary Fig. 2a,b. In addition to its presence in lysosomes, LAPTM4b was also detected at the plasma membrane in 54 and 49% of cells
co-expressing LAPTM4b with LAT1 or 4F2hc, respectively. P value was calculated by the Student’s t-test. Scale bars, 15 mm.
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reconstituted cells. In accord, knockdown of LAPTM4b resulted
in stimulation of autophagy (Supplementary Fig. 7). The effect of
LAPTM4b on EAA-mediated mTORC1 activation occurs
upstream of RagA, as evidenced by rescued activation of
mTORC1 in cells depleted of LAPTM4b and reconstituted with
a constitutively active RagA (RagA(Q66L), Fig. 3h). In support of
earlier work that implicated Leu inﬂux into cells in mTORC1
activation8, we show here that competition of LAT1-4F2hc-
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Figure 3 | LAPTM4b stimulates mTORC1 activation. (a,b) LAPTM4b enhances mTORC1 activation: HeLa cells stably transfected with control knockdown
(control KD), LAPTM4b knockdown (LAPTM4 KD, targeting its 30untranslated region) or LAPLTM4b KD reconstituted with mCh-LAPTM4b, were serum-
and nutrient-starved and tested for activation of S6K1 (pp70) following (or not) 15min stimulation with essential amino acids (EAAs). (a) A representative
immunoblot. (b) Quantiﬁcation of mTORC1 activation (pp70/p70 ratio) by LAPTM4b (data are mean±s.e.m., N¼ 3). (c–f) Time course of activation of
mTORC1 by LAPTM4b determined by S6K1 (pp70; c,d) or 4E-BP (p4E-BP; e,f) phosphorylation in HeLa cells stably expressing control KD, LAPTM4b KD or
LAPTM4b KD reconstituted with mCh-LAPTM4b (LAPTM4b KDþ LAPTM4b), serum- and nutrient-starved and stimulated with EAA for the indicated
times. DMEM: control (non-starved cells). (c,e) Representative immunoblots. (d,f) Quantiﬁcation of p70 and 4E-BP phosphorylation (activation),
respectively. (g) mTORC1 activation (S6K1 phosphorylation) in serum- and nutrient-starved cells by Leu (0.4mM, 15min) alone. The experiment was
performed as in a. (h) Rescue of mTORC1 activation in cells knocked down for LAPTM4b and expressing a constitutively active RagA, RagA(Q66L).
(g,h) Quantiﬁcation of data is depicted underneath the immunoblots. For all panels depicting quantiﬁcation: values are mean±s.e.m. (N¼ 3 independent
experiments). P values were calculated from Student’s t-tests.
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mediated Leu transport with D-Phe was rescued with the
constitutively active RagA mutant (Supplementary Fig. 5d),
although we currently do not know whether D-Phe inhibits Leu
inﬂux into cells, into lysosomes or both.
LAPTM4b promotes Leu entry into lysosomes. To evaluate the
effect of LAPTM4b on Leu transport, we tested the effect of
knocking down or reconstituting LAPTM4b on 3H-Leu entry into
cells and into lysosomes. Our results show that while knockdown
or reconstitution of LAPTM4b did not affect inﬂux of 3H-Leu into
cells via the plasma membrane (Fig. 4a; Supplementary Fig. 8a–d),
it caused a large reduction (B50%) of [3H]-Leu uptake into
lysosomes, which was rescued by re-expression of LAPTM4b
(Fig. 4b). LAPTM4b itself does not mediate Leu transport
(Supplementary Fig. 8a–d). In agreement with the ability of LAT1-
4F2hc to transport Leu into lysosomes, we found that the activity
of this Leu transporter is fully functional at pH 5.0, compatible
with intra-lysosomal pH (Supplementary Fig. 8e).
Together, these results demonstrate that LAPTM4b recruits
LAT1-4F2hc to lysosomes to promote Leu uptake into these
organelles and is required for mTORC1 activation. Consistent
with the above ﬁndings, LAPTM4b knockdown resulted in
attenuated cell proliferation and reduced cell size, which were
restored by re-expression of LAPTM4b (24 kDa) (Supplementary
Fig. 9).
LAPTM4b promotes mTORC1 activation via V-ATPase.
mTORC1 activation downstream of amino-acid stimulation was
previously shown to be mediated via intra-lysosomal amino-acid
stimulation of V-ATPase (Hþ -ATPase)11. Thus, we tested
whether the enhancement of mTORC1 activation by LAPTM4b
involves V-ATPase. We ﬁrst inhibited V-ATPase with
concanamycin A (ccA) and tested mTORC1 activation
following EAA stimulation of starved cells either depleted
(by knockdown) of LAPTM4b, or depleted and reconstituted
with LAPTM4b. Figure 5a shows that inhibiting V-ATPase
indeed reduced S6K1 phosphorylation (mTORC1 activation), as
previously reported11. Interestingly, reconstitution of LAPTM4b
after its knockdown was not able to properly restore mTORC1
activation in the presence of ccA (Fig. 5a). In accord, knockdown
of the V-ATPase V0c subunit, which is required for function of
this ATPase in mTORC1 activation11, prevented mTORC1
activation by LAPTM4b following EAA stimulation (Fig. 5b).
The apparent small additive effect of LAPTM4b knockdown and
ccA could be explained by a residual activity of the knocked-
down LAPTM4b. Taken together, these data show that
LAPTM4b-mediated activation of mTORC1 requires active
V-ATPase, suggesting that LAPTM4b functions upstream of
this Hþ pump and RagA.
Discussion
Our work presented here demonstrates that LAPTM4b promotes
Leu uptake into lysosomes and mTORC1 activation, most likely
by recruiting LAT1-4F2hc to the lysosomal membrane. We show
that LAPTM4b recruits the Leu transporter LAT1-4F2hc to
lysosomes, enhances Leu uptake into lysosomes and stimulates
mTORC1 activation via V-ATPase (Fig. 6). These ﬁndings not
only identify a functional Leu transporter (System L) at the
lysosomal membrane, but also help solve the puzzle of how
mTORC1 is activated by amino acids in the lysosome by an
inside-out mechanism (intra-lysosomal stimulation of V-ATPase)
originally noted by Sabatini et al.11. Since a strong knockdown of
LAPTM4b resulted in 50% reduction in lysosomal Leu uptake, it
is likely that other protein(s) aside from LAPTM4b may also
contribute to the recruitment of System L to lysosomes, and/or
that other Leu transporters may also contribute.
The mode of interaction between LAPTM4b and LAT1-4F2hc
(whether direct or indirect) is currently unknown. Our data show
that it does not involve the cytoplasmic N or C termini of
LAPTM4b (Supplementary Fig. 10a–f). Since removing the C
terminus, which caused endoplasmic reticulum (ER) retention of
both LAPTM4b and LAT1 (Supplementary Fig. 10g), did not
disrupt LAPTM4b:LAT1-4F2hc binding, we suspect that this
association takes place already at the ER, possibly during or soon
after protein translation. We also do not know whether
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LAPTM4b recruits LAT1-4F2hc to lysosomes directly from the
Golgi, from the plasma membrane or both.
LAT1-4F2hc is an amino-acid antiporter known to exchange
large neutral amino acids, in particular essential ones such as Leu,
across the plasma membrane6,19. Rate limiting for its function is
generally the cytosolic concentration of substrate amino acids,
because its intracellular afﬁnity is much lower than its
extracellular one. In the presence of a high intracellular
concentration of non-EAAs such as Gln, EAAs may thus be
accumulated in the cell via LAT1-4F2hc in exchange for the efﬂux
of non-EAAs. On the basis of the observed LAPTM4b-mediated
translocation of LAT1-4F2hc to lysosomes, we suggest that the
entry of Leu into lysosomes observed here and earlier11 may be
mediated by LAT1-4F2hc. Thus, not only a substantial cytosolic
Leu concentration would be required to drive its lysosomal Leu
uptake, but sufﬁcient intra-lysosomal neutral amino acids would
be necessary as exchange substrates to sustain LAT1-4F2hc
exchange. Possible sources of lysosomal amino acids include
hydrolysis of peptides/proteins activated by the V-ATPase-
mediated Hþ accumulation in lysosomes or uptake of large
neutral (non-essential) amino acids such as Gln into lysosomes
via directional/accumulative amino-acid transporters. Candidate
transporters could be in particular SNAT3 (SLC38A3) and
SNAT5 (SLC38A5), which co-transport Naþ plus non-essential
neutral amino acids in exchange for Hþ and thus also would be
activated by V-ATPase-mediated Hþ accumulation. Another
candidate is the Hþ -coupled lysosomal transporter PAT1, which
exports small neutral amino acids from the lysosome and was
proposed to regulate mTORC1 activation11, although the mode of
its regulation of mTORC1 is unclear20. The recently described
SLC38A9.1, which directly binds the Ragulator and Rag proteins,
is a low-afﬁnity Arg transporter that was proposed to function
instead as a transceptor to sense Arg21,22; it is not clear whether it
could provide counter-transport for Leu entry into lysosomes.
While our data indicate that the translocation of LAT1-4F2hc
with LAPTM4b to lysosomes plays a major role in the stimulation
of mTORC1 by EAAs, they do not reveal how and where
precisely amino acids such as Leu are sensed.
Finally, while the 35-kDa LAPTM4b isoform has been shown
to promote cancer via binding to p85 of PI3K and PI3K/Akt
activation16,17, it is possible that the 24-kDa isoform, which lacks
the binding site for p85, also has a role in cancer promotion by
enhancing mTORC1 activation via amino acids, a ﬁnding
supported by our observed stimulation of cell growth and
proliferation by this LAPTM4b isoform.
Methods
Cell lines and reagents including antibodies. The following antibodies (and
dilutions) were used: anti-LAMP1 (H4A3, 1:1,000), anti-Giantin (ab24586,
1:2,000), anti-ATP6V0c (ab104374, 1:100) and anti-mCherry (1C51, 1:1,000) from
Abcam; Anti-b-actin (#A2228, 1:10,000), anti-FLAG (#F1804, 1:10,000) and
anti-Calnexin (c4731, 1:1,000) from Sigma; anti-haemagglutinin (HA) (MMS-
101R, 1:1,000) from Covance, anti-HA (ab137838, 1:10,000) from Abcam,
anti-pS6K (pp70, 1:1,000) (Thr389, #9234S), anti-4E-BP1 (9452, 1:1,000), anti-
p4E-BP1 (T37/46, 1:1,000) (9459S) and anti-LAT1 (#5347S, 1:1,000, from Cell
Signaling and KAL-KE026, 1:500, from Cosmo Bio, Japan), anti-LAPTM4b
(APR62852_P050, 1:1,000, from Aviva Bio; EC-1 (1:1,000) from Abgent (a gift
from Dr Rou Li Zhou; and 18895-1-AP, 1:1,000, from Proteintech), anti-S6K (p70)
(SC-8418, 1:1,000) and anti-CD98/4F2hc (C-20) (sc-7095, 1:500) from Santa Cruz;
anti-LC3 (NB600–1384, 1:2,000) from Novus Biologicals; anti-FLAG M2 afﬁnity
agarose (A2220) and anti-HA agarose (#26181) were from Sigma and Pierce,
respectively. Secondary antibodies conjugated to horseradish peroxidase (1:10,000)
were purchased from Molecular Probes. Reagents for imaging: normal goat serum
(Jackson ImmunoResearch Laboratories Inc.), Alexa-Fluor 647 conjugated
ConcanavalinA (Invitrogen), Alexa-Fluor 488/647 Goat anti-mouse or anti-rabbit
2 antibody (Invitrogen) all used at 1:1,000 and 4,6-diamidino-2-phenylindole
(Molecular Probes, 1:5,000). Radioactive Leucine (Leu) uptake was monitored with
[3H]-Leu (PerkinElmer). Cell lines used originated from ATCC, unless indicated
otherwise. HeLa, MDA-MB-231 and HepG2 cells were maintained in full media
(DMEM supplemented with 10% fetal bovine serum, 100Uml 1 penicillin and
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Figure 5 | LAPTM4b requires active V-ATPase for mTORC1 activation.
(a) HeLa cells expressing control KD, LAPTM4b KD or LAPTM4 KD
reconstituted with HA-LAPTM4b (LAPTM4b KDþ LAPTM4b) were
serum- and nutrient-starved overnight and stimulated with EAA for 15min
in the presence/absence of the V-ATPase inhibitor Concanamycin A (ccA,
5 mM). mTORC1 activation was determined by immunoblotting for activated
S6K1 (pp70), as in Fig. 3 above. The top panel depicts a representative
experiment, while the bottom panel depicts the quantiﬁcation of three
separate experiments. (b) HeLa cells expressing control KD, LAPTM4b KD
or LAPTM4 KD reconstituted with HA-LAPTM4b (LAPTM4b
KDþ LAPTM4b) were transfected with V-ATPase shRNA (ATP6VOc
shRNA) to yield 60% knockdown. Cells were serum- and nutrient-starved
overnight, stimulated with EAA for 15min and analysed for S6K1 activation
as described in a. In b, the top panel depicts a representative experiment,
while the bottom panel depicts the quantiﬁcation of three separate
experiments. In a and b, values are mean±s.e.m. (N¼ 3). P values were
calculated from Student’s t-tests. NS, not signiﬁcant.
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100mgml 1 streptomycin), and BT549 cells were maintained in RPMI supple-
mented as for the other cells. Cells were transfected using Polyjet reagent
(Signagen). For stimulation experiments, cells were serum- and nutrient-starved
overnight in RPMI 1640 medium without amino acids, sodium phosphate powder
(#R8999-04A, US Biological) and stimulated with RPMI supplemented with
1 MEM (minimal essential medium (or EAA), Life Technologies, with
amino-acid composition provided in: http://www.lifetechnologies.com/ca/en/
home/technical-resources/media-formulation.164.html); uncropped blot images
are shown in Supplementary Fig. 11.
cDNA constructs. Human ORFeome complementary DNA (cDNA) entry clones
(pDONR223) for LAPTM4b (AAH31021.1), LAT1/SLC7A5 (BC039692), 4F2hc/
SLC3A2 (BC003000) and LAMP1 (BC021288) were obtained from SIDNET/
SPARC (SickKids). Each construct was N-terminally tagged with either Flag or
mCherry (mCh) using the Gateway cloning system (Invitrogen). LAPTM4b
truncation mutants: DC-LAPTM4b (amino acids 1–181), DN-LAPTM4b (amino
acids 21–226) and DNDC-LAPTM4b (amino acids 21–181) were sub-cloned from
LAPTM4b wild-type cDNA into pcDNA3.1-nHA using the Gateway system.
Constitutively active CFP-tagged Rag A (Q66L) was obtained from Dr John
Brumell (Hospital for Sick Children).
Generation of stable LAPTM4b knockdown cell lines. HeLa cells were trans-
fected with either one of three LAPTM4b-speciﬁc shRNAs: V2LHS_175452
(targets LAPTM4b open-reading frame (ORF), V3LHS_340114 (targets ORF),
V3LHS_405603 (targets 30 untranslated region) or nonspeciﬁc shRNA all in the
pGIPZ vector from Open Biosystems. V3LHS_405603 (shRNA 603) was used in all
experiments, unless otherwise indicated. The cells were maintained in growth
media supplemented with 1 mgml 1 puromycin until colonies formed. For
generating stable LAPTM4b knockdown in MDA-MB-231, HepG2 and BT549 cells
lines: MDA-MB-231, HepG2 and BT549 cells were transfected with either shRNA
to knockdown LAPTM4b (V3LHS_405603) or pGIPZ-Ctrl (control). Transfected
cells were selected in Puromycin (0.25 mgml 1 for MDA-MB-231 and 1 mgml 1
for HepG2 and BT549) in DMEMþ fetal bovine serum and antibiotics. Green
ﬂuorescent protein-positive colonies were selected and expanded as individual
clones. LAPTM4b knockdown efﬁciency was monitored by quantitative PCR using
the LAPTM4b unique primers from Integrated DNA Technologies (Supplementary
Table 2).
Afﬁnity-tag immunoprecipitation and mass spectrometry. The protocol
designed for afﬁnity-tag IP of HA-LAPTM4b-WT and sample preparation for
tandem mass spectrometry (MS) was modiﬁed from a previously established
protocol23. Brieﬂy, HeLa cells were transiently transfected with HA-LAPTM4b-WT
for 48 h. Cells were lysed on ice in lysis buffer (50mM Hepes, pH 7.5, 150mN
NaCl, 1% Triton X-100, 10% glycerol, 1.5mM MgCl2, 1.0mM EGTA,
supplemented with 10 mgml 1 leupeptin, 10 mgml 1 aprotinin, 10mgml 1
pepstatin and 1mM phenylmethanesulfonylﬂuoride) and HA-LAPTM4b was
immunoprecipitated with anti-HA agarose beads at 4 C for 3 h. Beads were
washed three times with IP wash buffer (20mM Hepes, pH 7.5, 150mM NaCl,
10% glycerol and 0.1% Triton X-100) and twice with HPLC-grade H2O. Bound
proteins were eluted with 0.1% triﬂuoroacetic acid and peptides were generated by
trypsin digestion (Biolab, TPCK, #P8101S). Peptide fragments were desalted using
Pierce C-18 Spin Columns (Thermo Scientiﬁc, #89870, Lot#NJ176772). The eluted
peptide mix was analysed by shotgun liquid chromatography tandem mass
spectrometry (MS/MS). All MS/MS samples were analysed using Sequest (Thermo
Fisher Scientiﬁc, San Jose, CA, USA; version 1.3.0.339) and X! Tandem (The GPM,
thegpm.org; version CYCLONE (2010.12.01.1)). Scaffold (version Scaffold_3.6.4,
Proteome Software Inc., Portland, OR) was used to validate MS/MS-based peptide
and protein identiﬁcations.
Immunoﬂuorescent confocal microscopy. HeLa cells were cultured on poly-D-
lysine-coated coverslips in six-well plates and transiently transfected with the
indicated cDNA. At 24 h post transfection, wells were washed three times with cold
1ml PBS and incubated for 5min with Alexa-Fluor-647-conjugated Con-
canavalinA (1:1,000) on ice to visualize the plasma membrane. The cells were ﬁxed
with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and incubated
with 1:100 normal goat serum in 3% skim milk (30min). Slides were stained for 1 h
with either rabbit anti-HA (1:1,000), mouse anti-human LAMP1 (1:1,000), rabbit
anti-human Giantin (1:2,000) or rabbit anti-human Calnexin (1:1,000) in 3% skim
milk. After three PBS washes, cells were incubated with goat anti-mouse or
anti-rabbit Alexa 488/647 Fluor-conjugated 2 antibody and brieﬂy stained with
4,6-diamidino-2-phenylindole. Coverslips were mounted with Dako Cytomation.
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Figure 6 | Proposed role of LAPTM4b in activation of mTORC1 via recruitment of the Leu transporter to lysosomes. The lysosomal protein LAPTM4b
recruits LAT1-4F2hc (the Leu transporter) to the lysosome, promoting entry of Leu and other EAA into the lysosome, stimulating activation of V-ATPase
and hence mTORC1 activation (via the Ragulator, RagA/B-GTP and Rheb-GTP).
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Images were acquired using a Quorum WAveFX-X1 spinning disc confocal system
at  60 magniﬁcation with an Olympus S-Apo  60/1.35 oil objective (Quorum
Technologies Inc., Guelph, Canada). Co-localization was assessed by Volocity 6.0.1
(PerkinElmer) and expressed as Pearson’s correlation coefﬁcients.
Co-immunoprecipitation assays. HeLa cells were co-transfected with the speciﬁed
cDNA constructs and lysed in lysis buffer. Co-IP of FLAG-LAT1, FLAG-4F2hc,
mCherry-SNAT2 or mCherry-ASCT2 with HA-LAPTM4b was determined by IP of
either FLAG-LAT1 or FLAG-4F2hc from 1mg of cleared cell lysate with either anti-
Flag M2 afﬁnity beads and immunoblotting with anti-HA antibody, or IP of HA-
LAPTM4b with anti-HA antibody coupled to Protein G Sepharose (Bioshop) and
immunoblotting with anti-mCherry antibody. Endogenous Co-IP of LAT1 and
LAPTM4b was performed by IP of LAT1 from 1.5mg of cleared HeLa cell lysate and
immunoblotting with anti-LAPTM4b antibodies. Co-IP of HA-LAPTM4b DN, DC
and DNDC mutants with FLAG-4F2hc was determined by IP of LAPTM4b as above,
and immunoblotting with anti-FLAG antibody.
Amino-acid stimulation and mTORC1 activation. Cells were serum-starved
overnight in RPMI 1,640 medium without amino acids and were restimulated with
RPMI supplemented with EAA (or MEM) or 0.4mM L-leucine (LEU222.25, Bioshop)
for the indicated times. For knockdown of ATP6V0c experiment, HeLa cells were
transfected with either control or ATP6V0c-715 siRNA (Abcam) and HA-LAPTM4b
48 h prior to serum starvation. For the ccA experiments, cells were transfected with
HA-LAPTM4b where indicated and then treated with 5mM ccA (Sigma) for 1 h prior
to stimulation. For Rag A (Q66L) rescue experiments, HeLa cells were transfected
with CFP-Rag A (Q66L) for 48 h, starved for 1.5 h and stimulated with EAA with or
without 20mM D-phenylalanine (P1751, Sigma) for the indicated times. Cells were
lysed in lysis buffer and mTORC1 activation was monitored using anti-pT389-S6K1
and anti-p4E-BP1 antibodies. All blots were imaged using the Odyssey Imaging
system and quantiﬁed using Image Studio version 3.1.4 (LI-COR).
Leu uptake by lysosomes. HeLa cells stably expressing control, LAPTM4b
knockdown (KD), or LAPTM4b KD reconstituted with LAPTM4b, were grown in
four 10-cm dishes and transfected with FLAG-Lamp1. At 24 h post transfection, cells
were starved overnight in RPMI and then stimulated with RPMI supplemented with
MEM (EAA, which includes 0.4mM Leu) and 4 mCi [3H]-Leu per 5ml per dish.
Samples were incubated for 10min, at which point the amount of Leu taken up by
the lysosomes was measured, as described11. Brieﬂy, for each cell type (control KD or
LAPTM4b KD), cells from all four plates were pooled to generate a post-nuclear
supernatant fraction by lysing cells through a 23-G needle attached to a 1-ml syringe
in fractionation buffer (50mM KCL, 90mMK-gluconate, 1mM EGTA, 5mM
MgCl2, 50mM sucrose, 20mM HEPES, pH7.4, supplemented with protease
inhibitors (leupeptin, pepstatin and aprotinin, 10mgml 1). Samples were spun for
10min at 425g (4 C). The post-nuclear supernatant was divided into 3 aliquots and
spun at 20,000g for 15min at 4 C. The resulting subcellular fraction (pellet) that
contains the FLAG-bound lysosomes was resuspended and topped up to 1ml of
fractionation buffer. Thirty ml anti-FLAG M2-afﬁnity agarose was added to each
sample and incubated at 4 C for 2 h. Samples were spun for 1min at 425g and
washed three times with cold fractionation buffer. The afﬁnity beads with bound
lysosomes were transferred to scintillation vials using cut pipet tips and [3H]-Leu
radioactivity was measured with a scintillation counter (Hidex 300 SL, Southern
Scientiﬁc) using the MiKrowin 2,000 software (Mikrotek Laborsysteme GmbH).
100% counts in lysosomes ranged from B40 to 130 counts per min (similar to the
values described by Zoncu et al.11). The experiment was repeated three times, each in
triplicates. Successful enrichment for the lysosomal fraction was monitored by
SDS–polyacrylamide gel electrophoresis of lysates at various stages of the isolation.
For oocyte experiments, [3H]-Leu uptake was carried out after injection of
cRNA encoding a fusion protein of LAT1-4F2hc into oocytes as detailed in ref. 24.
Cell proliferation and cell size and viability assays. HeLa cells (control KD,
LAPTM4b KD or mCherry-LAPTM4b reconstituted into LAPTM4b KD cells)
were seeded at 4,500 cells per well in a 96-well plate in duplicates, and cell
proliferation was measured for the indicated times using the Alamar Blue assay
(Invitrogen) as per the manufacturer’s instructions. Absorbance at 600 nm was
measured using the Spectra Max 190 plate reader (Molecular Devices). All
absorbance readings were normalized to day 0. For the cell size assay, HeLa cells
(control KD, LAPTM4b KD or mCherry-LAPTM4b reconstituted into the
LAPTM4b-depleted cells) were seeded at 30,000 cells per well in a 24-well plate in
duplicates and cell size was measured using the Cellomics VTI (Thermo Fisher)
and a modiﬁed Target Activation algorithm. Individual cells were identiﬁed and
deﬁned by green ﬂuorescent protein ﬂuorescence, and the image pixels were used
to determine cell size for individual cells. For mCherry-LAPTM4b-reconstituted
cells, expression of RFP was used to gate selected cells such that only cells with a
predetermined level of LAPTM4b-RFP ﬂuorescence were included in measure-
ments for cell size. At least 10,000 cells were measured per treatment, and the mean
for the number of cells analysed was calculated for each treatment. For the viability
assay, HeLa cells were starved overnight and cell viability was determined using the
Trypan Blue stain (Invitrogen, T10282) and quantitated using the Countess
Automated Cell Counter (Life Technologies).
Cycloheximide pulse-chase experiments. HeLa cells (control KD, LAPTM4b KD
or mCherry-LAPTM4b reconstituted into LAPTM4b KD cells) were treated with
50 mM cycloheximide for the indicated times. Cells were lysed and the stability of
endogenous LAT1 and 4F2hc was monitored by immunoblotting. The relative
abundance of each protein was normalized to actin. Images were quantiﬁed in
Image Studio version 3.1.4 (LI-COR).
Autophagy experiments. HeLa cells stably knocked down for LAPTM4b (or
control) were starved and treated with 50 mM chloroquine for the indicated times,
lysed as described above and autophagic rate (ﬂux) was monitored using LC3
antibodies. All blots were imaged using the Odyssey Imaging system and quantiﬁed
using Image Studio version 3.1.4 (LI-COR). For autophagy immunoﬂuorescent
experiments, LAPTM4b stable knockdown and control cells were starved for 2 h in
the presence of 50mM chloroquine, ﬁxed with 4% paraformaldehyde and per-
meabilized for 15min with cold 95% methanol. Cells were blocked for 1 h with 1%
BSA (in PBS) and incubated overnight in LC3 antibody (1:200) at 4 C before being
processed for imaging using Volocity, as above.
Data analysis. For all quantitative experiments (unless otherwise indicated), the
Student’s t-test (unpaired, two tailed) was used.
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